Skip to main content
Evidence Snapshot

Ribosomal protein S6 kinase beta-1

CHEMBL4501 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:14Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4501
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ribosomal protein S6 kinase beta-1 as ChEMBL target CHEMBL4501, mapped to UniProt P23443. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ribosomal protein S6 kinase beta-1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4501
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P23443
Ribosomal protein S6 kinase beta-1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Ribosomal protein S6 kinase beta-1 matters

As of 2026-09-13

Ribosomal protein S6 kinase beta-1 is reviewed as Ribosomal protein S6 kinase beta-1 (UniProt P23443); Ribosomal protein S6 kinase beta-1 shows clinical signal disease relevance led by cancer. 4 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 8 approved drugs, 3802 compounds, and 513 assays, with lead potency reaching pChEMBL 10.2.

Disease context
cancer

Ribosomal protein S6 kinase beta-1 shows clinical signal disease relevance led by cancer. 4 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include LY-2584702.

Start review with cancer because it currently carries clinical signal support. Linked drugs include LY-2584702. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 3802 compounds, and 513 assays for this target. The dominant activity type is IC50. CHEMBL3936990 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL3936990 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Ribosomal protein S6 kinase beta-1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P23443, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3802
Total Compounds
513
Total Assays
8
Approved Drugs
IC50: 2080.0, KI: 731.0, KD: 312.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3936990
 10.2 IC50 —
No preferred name
CHEMBL3899716
 10.0 IC50 —
No preferred name
CHEMBL3966806
 10.0 IC50 —
No preferred name
CHEMBL3675393
 9.9 IC50 —
No preferred name
CHEMBL3675394
 9.8 IC50 —

Approved Drugs

Structure Compound First Approval
NINTEDANIB
CHEMBL502835
 2014
BOSUTINIB
CHEMBL288441
 2012
CRIZOTINIB
CHEMBL601719
 2011
SUNITINIB
CHEMBL535
 2006
SORAFENIB
CHEMBL1336
 2005
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:14Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4501